# RECURSION PHARMACEUTICALS IN (RXRX)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/RXRX/

- Reporting holders: 10
- Reported value: $1.4M
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Green Alpha Advisors, LLC](https://holderbook.com/funds/1439207-green-alpha-advisors-llc/) | $988.7K | 239,404 | 0.7% | 13 |
| [Whalen Wealth Management Inc.](https://holderbook.com/funds/1894447-whalen-wealth-management-inc/) | $199.4K | 48,282 | 0.1% | 1 |
| [Wedmont Private Capital](https://holderbook.com/funds/1904274-wedmont-private-capital/) | $74.8K | 18,943 | 0.0% | 14 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $53.6K | 12,978 | 0.0% | 12 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $48.8K | 11,820 | 0.0% | 6 |
| [Quintet Private Bank (Europe) S.A.](https://holderbook.com/funds/1977290-quintet-private-bank-europe-s-a/) | $35.6K | 8,620 | 0.0% | 5 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $17.4K | 4,209 | 0.0% | 12 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $15.9K | 3,853 | 0.0% | 10 |
| [Roxbury Financial LLC](https://holderbook.com/funds/2054149-roxbury-financial-llc/) | $4.1K | 1,000 | 0.0% | 1 |
| [Marquette Asset Management, LLC](https://holderbook.com/funds/1395067-marquette-asset-management-llc/) | $740 | 179 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 10 | $1.4M |
| Q2 2026 | 352 | $1.5B |
| Q1 2026 | 339 | $1.1B |
| Q4 2025 | 339 | $1.4B |
| Q3 2025 | 329 | $1.7B |
| Q2 2025 | 339 | $1.7B |
| Q1 2025 | 340 | $1.7B |
| Q4 2024 | 320 | $2.1B |
| Q3 2024 | 266 | $1.8B |
| Q2 2024 | 270 | $1.9B |
| Q1 2024 | 250 | $2.2B |
| Q4 2023 | 200 | $2.1B |